Valneva’s inactivated COVID-19 vaccine candidate, VLA2001
To help fight the pandemic, specialty vaccine company Valneva has developed VLA2001. As of April 2021, it is the only inactivated vaccine candidate in clinical trials against COVID-19 in clinical development in Europe.
About the vaccine candidate VLA2001
- Adjuvanted with Alum and CpG 1018
- Whole virus candidate
- Vero-cell based
- Using the manufacturing platform of Valneva’s commercial Japanese encephalitis (JE) vaccine
Valneva reported positive Phase 1/2 data for its COVID-19 vaccine candidate
Valneva reported positive Phase 1/2 trial data for VLA2001 at the beginning of April 2021 (Press release). VLA2001 was well tolerated with no safety concerns identified. In the high dose group, IgG seroconversion rate was 100 percent, and neutralizing antibody titers were at or above levels generally seen in convalescent sera. Based on the data assessed, the Company has decided to advance the high dose into the Phase 3 clinical trial, expected to start by the end of April 2021, subject to regulatory approval.
Agreement with the UK & discussions with the EC
In September 2020, Valneva announced a collaboration with the UK government, which has the option to purchase up to 190 million doses through 2025. Following an initial order for 60 million doses to be delivered in 2021, the UK Government exercised an option in January 2021 to order 40 million for supply in 2022. This brings the total volume of the Valneva vaccine ordered by the UK Government to 100 million doses and the UK Government retains options over a further 90 million doses for supply between 2023 and 2025. The UK government is also investing up-front in the scale up and development of the vaccine.
In January 2021, Valneva announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of VLA2001.
Read more about VLA2001 here: https://valneva.com/research-development/covid-19-vla2001/